Alerta

用于治疗BRCA阴性/同源修复正常癌症的IL-12基因疗法

Resumen de: WO2024059630A2

The present disclosure relates to a method for treating cancer in a subject that is BRCA-negative and homologous repair proficient (HRP), the method comprising administering to the subject a nucleic acid vector (e.g., a plasmid) comprising a polynucleotide that encodes an interleukin-12 (IL-12) formulated with a lipopolymer (e.g., a nanoparticle). In some aspects, the method further comprises administering to the subject an anticancer agent (e.g., a chemotherapeutic agent), an antibody or antigen-binding fragment thereof that specifically binds a vascular endothelial growth factor (VEGF) (anti-VEGF antibody), an immune checkpoint inhibitor, or any combination thereof.

一种纳米探针、其制备方法及其在制备治疗癌症药物中的应用

Resumen de: CN120168433A

本发明提供了一种纳米探针、其制备方法及其在制备治疗癌症药物中的应用。本发明提供的纳米探针。其纳米探针包括131I、癌细胞膜、碱基捕获剂和血清白蛋白修饰硫化铜纳米粒子。本发明还提供的纳米探针对难治性甲状腺癌实现更高效的治疗，其显著提升了抗肿瘤效果，实验可能证明它比单一治疗方式提高了癌细胞的杀伤率，通过CCM包裹显著降低了放射性物质对非癌组织的损伤，同时CuS在近红外光照射下的局部热效应也减少了周围正常组织的损害，该探针不仅可以用于治疗，还可以用于肿瘤成像，结合诊断与治疗，实现“诊疗一体化”。

一种二元有机-无机有序胶囊及其制备方法

Resumen de: CN120168432A

本发明公开了一种二元有机‑无机有序胶囊结构的制备方法。本发明二元胶囊结构的制备方法包括以下步骤：首先，使用三水合四氯金酸溶液来合成金纳米立方体和金纳米球；随后，在金纳米立方体和金纳米球表面接枝聚苯乙烯；最后，采用乳液界面受限组装的方法制备二元有机‑无机有序胶囊结构。本发明通过对两种无机纳米粒子表面聚合物分子量的调节，可有效调控两种纳米粒子的间距、排列与取向。

负载mRNA纳米抗体的脂质纳米粒及其制备方法和其应用

Resumen de: CN120168431A

本发明涉及一种负载纳米抗体mRNA的脂质纳米粒，所述脂质纳米粒含有脂质混合物和纳米抗体mRNA，其中，所述脂质混合物和纳米抗体mRNA的N/P值为3‑10：1，所述纳米抗体的氨基酸序列如SEQ ID NO：1所示，所述纳米抗体mRNA的核苷酸序列如SEQ ID NO：2所示。本发明将体外转录获得的纳米抗体mRNA，包载于脂质纳米粒中，使得纳米抗体能够在活细胞中表达，制得的负载纳米抗体mRNA的脂质纳米粒，具有靶向性高、半衰期长、包封率高、稳定性好、安全有效等优点。

一种靶向鳞状细胞癌的CGKRK修饰的紫草素-锰纳米颗粒

Resumen de: CN120168511A

本发明涉及一种靶向鳞状细胞癌的CGKRK修饰的紫草素‑锰纳米颗粒，属于抗肿瘤药物技术领域。本发明的CGKRK修饰的紫草素‑锰纳米颗粒，包括脂质体外壳和封装于脂质体外壳中的紫草素和锰离子；所述脂质体外壳包括蛋黄卵磷脂、胆固醇、磷脂‑聚乙二醇‑细胞穿透肽。本发明的CGKRK修饰的紫草素‑锰纳米颗粒的平均粒径为100nm左右，分散均一，符合成品质量要求；紫草素和锰离子的包封率高，紫草素包封率可达96.41％，锰离子包封率可达10.08％；有效抑制鳞状细胞癌生长，诱导肿瘤细胞发生程序性坏死，重塑肿瘤局部免疫微环境；具有良好的生物安全性，不会对宿主造成肝毒性及肾毒性等不良反应。

一种替曲朵辛纳米颗粒及其制备方法与应用

Resumen de: CN120168436A

本发明属于药物领域，本发明提供一种替曲朵辛纳米颗粒及其制备方法与应用。所述纳米颗粒包括：内核和外壳；所述内核包括活性成分和助溶剂；所述活性成分包括替曲朵辛或其药学上可接受的盐；所述外壳包括至少两层纳米粒外壳；每层所述纳米粒外壳包括一层聚合物基质层和一层稳定剂层；所述聚合物基质层中的聚合物基质包括聚乳酸‑羟基乙酸共聚物‑聚乙二醇。本发明所提供的纳米颗粒稳定性好，可在室温条件下长期储存，解决了替曲朵辛制剂在室温条件下不稳定的问题，此外，本发明所提供的纳米颗粒缓释效果好，可在至少24小时内持续释放。

免疫佐剂组合物及其制备方法和用途

Resumen de: WO2025124295A1

Provided are an immunologic adjuvant composition, a preparation method therefor and a use thereof. The immunologic adjuvant composition comprises an immune activator and a liposome used for loading the immune activator, wherein the immune activator comprises a saponin and a CpG oligodeoxynucleotide. The immunologic adjuvant composition can induce an immune response of a mammal against a human herpesvirus and/or hepatitis B virus, and can induce a strong level of cellular immune response. By using the liposome to simultaneously load a QS21 and the CpG oligodeoxynucleotide, the two have a better synergistic effect in the aspect of promoting cellular immunity, and can induce a stronger level of cellular immune response compared to a commercially available Shingrix vaccine.

一种可电离脂质化合物、脂质体、脂质纳米颗粒及其应用

Resumen de: CN118638021A

The invention provides an ionizable lipid compound, a liposome, a lipid nanoparticle and application thereof. The ionizable lipid compound is selected from a structure as shown in a formula I in the specification. The lipid nanoparticles prepared from the ionizable lipid compound provided by the invention are uniform in particle size distribution and low in cytotoxicity, and the active substances can be specifically delivered to cells, tissues or organs in a targeting manner, so that the targeting delivery of the active substances is realized. # imgabs0 #

禽冠状病毒mRNA疫苗、质粒及其制备方法

Resumen de: CN120168623A

本发明公开了一种禽冠状病毒mRNA疫苗、质粒及其制备方法，旨在提供一种禽源冠状病毒mRNA疫苗，该免疫原性高，安全性好的疫苗，所述的所述的禽冠状病毒mRNA疫苗是核苷酸脂质纳米粒包裹mRNA，所述的mRNA为核苷酸序列如SEQ ID NO.1所示的mRNA‑N；或者核苷酸序列如SEQ ID NO.2所示mRNA‑N‑Mosaic，属于疫苗技术领域。

一种氢钙复合体的制备方法及其应用

Resumen de: CN120167628A

本发明提供一种氢钙复合体的制备方法，包括以下步骤：采用超临界CO2流体处理珊瑚钙原料，去除杂质并形成微孔结构；通过高压脉冲电场将氢分子嵌入具有微孔结构的珊瑚钙中采用脂质体包覆经过上述步骤处理的珊瑚钙，即可得到氢钙复合体；本发明还提供氢钙复合体的应用。通过上述制备方法可以有效提高钙的吸收率和氢分子的稳定性，拓展了氢钙复合体在骨骼健康补充剂、解酒护肝产品及功能性食品添加剂等领域的应用潜力。

提高药物肝脏靶向的脂质纳米颗粒及其制备方法和应用

Resumen de: CN120168430A

本发明具体公开了提高药物肝脏靶向的脂质纳米颗粒及其制备方法和应用，涉及生物医药技术领域。本发明提供了一种用于肌肉注射的脂质纳米颗粒，所述脂质纳米颗粒包含PC类磷脂和活性成分，所述活性成分为核酸类药物，所述脂质纳米颗粒能够提高活性成分的肝脏表达或分布。为开发新的治疗策略提供了理论依据和实验基础，具有很好的临床转化和临床应用前景。

用于靶向炎症性巨噬细胞的纳米平台以及包含其的用于预防或治疗炎症性疾病的组合物

Resumen de: WO2024112181A1

The present invention relates to a nanoplatform for targeting inflammatory macrophages, and a composition for preventing or treating inflammatory diseases by using same. The nanoplatform for targeting inflammatory macrophages, according to the present invention, has a glucosyl group bound thereto as a delivery material so that inflammatory macrophages can be selectively targeted, and can exhibit the effects of inhibiting an inflammatory reaction of damaged cells or tissue, and restoring mitochondrial function so as to inhibit cell death, and thus can be provided as a composition for effective prevention or treatment of inflammatory diseases, especially kidney diseases.

细胞组合物

Resumen de: WO2024100137A1

Non-human animal-derived cell composition comprising a plurality of non-human animal- derived cells, wherein the cells comprise at least one exogenous supplement comprised in a carrier selected from the group consisting of nanocarriers, nanoparticles, micelles, liposomes or vesicles is described. The cell composition is characterized by having improved organoleptic properties, such as an improved flavour, colour, texture or mouthfeel and/or having a meat like flavour. Methods of producing the same and comestibles comprising the same are also described.

一种光热剂及其制备方法和在温和光热疗法联合阿贝西利治疗肿瘤中的应用

Resumen de: CN120168435A

本发明涉及一种光热剂及其制备方法和在温和光热疗法联合阿贝西利治疗肿瘤中的应用。该光热剂具有优越的光热效应和光稳定性，用于温和光热‑阿贝西利联合治疗时，先通过阿贝西利诱导肿瘤细胞衰老，再利用温和光热疗法精准打击脆弱的老化癌细胞，形成“双重打击”效应。该疗法显著提高治疗效果，同时减少副作用，因温和光热能量较低且组合疗法更具靶向性；此外，治疗采用分步进行，先诱导衰老再实施光热治疗，可根据患者反应调整方案，提高安全性和可控性，并降低急性毒性风险。本发明创新性地结合药物诱导衰老与物理治疗，为难治性或复发性癌症提供了新的治疗途径。

一种普鲁士蓝治疗生物膜感染的纳米抗菌剂及其制备方法与应用

Resumen de: CN120168633A

本发明公开了一种普鲁士蓝治疗生物膜感染的纳米抗菌剂及其制备方法与应用，该纳米抗菌剂以中空普鲁士蓝（Hollow Prussion Blue,HPB）为载体装载具有抗炎及抗氧化作用的物质，通过透明质酸（HA）修饰的单宁酸（TA）与高价态金属离子螯合形成的金属多酚网络结构(metal‑phenolic networks,MPNs)对其进行封装制得。该纳米抗菌剂各组分共同协同作用，其中该抗菌剂中通过透明质酸修饰的TA与高价态金属离子螯合形成的MPNs具有很好的光热性能，可以将光能转换为热能用于光热治疗。本发明构建了用于光热抗菌消炎的纳米颗粒，以实现抗生物膜和抗炎作用的综合治疗，并促进感染部位的愈合。且该抗菌剂生物相容性良好，生物安全性高，非常适合代替抗生素治疗生物膜感染。

一种含有缩硫酮键的ROS响应型纳米粒子的制备及应用

Resumen de: CN120168434A

本发明涉及一种含有缩硫酮键的ROS响应型纳米粒子的制备及应用，可有效解决姜黄素的生物相容性差、水溶性差以及不可控释放等问题。所述材料包括姜黄素、4‑羧基苯硼酸、壳寡糖和缩硫酮二酸。本发明通过4‑羧基苯硼酸对壳寡糖进行修饰，随后缩硫酮二酸交联得到ROS响应性的聚合物。该聚合物与姜黄素、葡萄糖氧化酶在溶液中自组装构筑ROS响应的纳米粒子。本发明的制备的纳米粒子由于引入ROS敏感的缩硫酮键和硼酸酯键，肿瘤微环境刺激下实现了姜黄素在肿瘤部位的可控释放。此外，包封的葡萄糖氧化酶能够催化肿瘤组织处过表达的葡萄糖产生过氧化氢，提升了肿瘤细胞的ROS浓度，增强药物释放效率，有效提高药物对乳腺癌的治疗效果。

重组AAV载体及其用途

Resumen de: WO2023108507A1

Provided is a recombinant adeno-associated virus (rAAV) capsid protein, comprising an amino acid sequence of 11 contiguous amino acids X1X2X3X4X5X6X7X8X9X10Q, rAAV vector comprising the same, and the use thereof.

LIPID NANOPARTICLES LYOPHILIZATION METHODS AND COMPOSITIONS

Resumen de: AU2023393613A1

The invention provides a lyophilized nucleic acid lipid nanoparticle (NALNP) comprising (a) a lipid nanoparticle comprising a nucleic acid, and (b) a lyophilization buffer comprising a sugar, a lyophilization reagent, and a pharmaceutically acceptable diluent, as well as a method of preparing same.

GLYCOLIPID COMPOSITIONS

Resumen de: WO2025124711A1

Provided herein are particles and compositions comprising one or more glycolipids and a nucleic acid, wherein the one or more glycolipids are represented by, for example, formula I: G1-G2-G3 or a pharmaceutically acceptable salt thereof.

ANTIBACTERIAL DRUG-ELUTING COMPOSITIONS AND METHODS

Resumen de: US2025195446A1

The present disclosure describes compositions that can be used in the treatment of an ocular injury or disease in a subject in need thereof. Methods of preparing the compositions are also described. The compositions can include one or more nanoparticles encapsulating a hydrophilic therapeutic agent; gelatin methacryloyl (GelMA); hyaluronic acid-glycidyl methacrylate (HAGM); and a visible light-activated photoinitiator.

CELL TYPE SELECTIVE DELIVERY OF EXOSOME CARGO USING NOTCH LIGAND-RECEPTOR SYSTEM

Resumen de: US2025195448A1

Provided herein are engineered exosomes and uses thereof for cell-type selective delivery of cargo. In particular, provided herein are engineered exosomes expressing a Notch ligand binding domain and uses thereof for targeted delivery of therapeutic cargo to cells expressing Notch ligand, such as neurons.

MELT PROCESSED VIRAL NANOPARTICLE CONSTRUCTS

Resumen de: US2025195449A1

A melt processed viral nanoparticle construct for delivery of virus or virus-like particles to a site of interest includes a degradable polymer matrix and a plurality of virus or virus-like particles encapsulated within the degradable polymer matrix. The nanoparticle construct upon administration to the site of interest providing a sustained release of the virus or virus-like particles and/or nanoparticles upon degradation of the polymer matrix.

Oral Rapamycin Nanoparticle Preparations and Use

Resumen de: US2025195435A1

Oral preparations of microcapsules and nanoparticles including an inhibitor of the mammalian target of rapamycin. The preparations are intended to assist with the treatment and prevention of cancer, neurocognitive dysfunction, genetically predisposed disorders, and age-related disorders. The embodiments discussed address the present need for alternative preparations or manufacturing processes that ensure efficacy while improving other performance characteristics such as storage stability, biodistribution, dosage cost, etc.

LIPID NANOPARTICLES FOR TARGETED DELIVERY OF MRNA

Resumen de: US2025195431A1

Disclosed are compositions including a pharmaceutical agent and a lipid composition; wherein the pharmaceutical agent is assembled with the lipid composition; and the lipid composition comprises a lipidoid having structural Formula (I):or a pharmaceutically acceptable salt thereof, wherein Ra, Rb1, Rb2, Rb3, Rb4, n1 and n2 are as described herein.

LNCRNA TRANSCRIPTS IN MELANOMAGENESIS

Nº publicación: US2025197864A1 19/06/2025

Solicitante:

THE REGENTS OF THE UNIV OF CALIFORNIA [US]
The Regents of the University of California

Resumen de: US2025197864A1

The invention provides compositions and methods for treatment of melanoma and other cancers. In particular, the invention provides a single or double-stranded nucleic acid that inhibits a certain group of long non-coding RNAs (lncRNAs) that have been discovered to be associated with melanoma. Inhibition of these lncRNAs in melanoma cells and xenograft mouse models leads to inhibition of cell proliferation, induction of apoptosis, and reduced cancer cell growth. The invention also relates to a method of inhibiting cancer cell growth with specific kinase inhibitors that have been found to show similar inhibition effects as the nucleic acids targeting the lncRNAs. The single or double-stranded nucleic acid and the specific kinase inhibitors constitute a novel therapeutic strategy in the treatment of melanoma and other cancers.